Full text is available at the source.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by complex metabolic, inflammatory, and fibrogenic interactions.
- Qualitative changes in lipid species and protein signaling networks are involved in the initiation and progression of MASLD.
- Bioactive lipids like ceramides and free cholesterol are linked to lipotoxicity, mitochondrial dysfunction, inflammasome activation, and fibrosis.
- Key pathways related to inflammation, cellular aging, and the activation of liver cells have been identified through proteomic analyses.
- Current pharmacological agents may influence molecular signatures associated with MASLD, extending beyond their metabolic roles.
- Combining lipidomic and proteomic insights could enhance disease classification, biomarker identification, and the creation of targeted treatment approaches.
Simplified